Amgen vs TCS: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. TCS was founded in 1968 by J.R.D. Tata, F.C. Kohli and is led by K Krithivasan.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
TCS
J.R.D. Tata
J.R.D. Tata was chairman of Tata Sons from 1938 to 1991. Under his leadership the group set up Tata Computer Centre in 1968, which became Tata Consultancy Services, initially to provide data-processing and management-consultancy services to Tata companies.
F.C. Kohli
Faqir Chand Kohli (1924-2020) moved from Tata Electric Companies to lead TCS in 1969 and served as its first general manager and later CEO until 1996.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
TCS
- F. C. Kohli1969–1996
Co-founder and First CEO
By the time Kohli stepped down from executive responsibility in 1996, TCS-trained programmers numbered in the hundreds of thousands and had helped launch India's broader IT-export industry, earning Kohli the title 'Father of the Indian IT Industry' and India's…
Source - N. Chandrasekaran2009–2017
CEO
He became chairman of Tata Sons in February 2017 and also chairs TCS's board and Air India.
Source - Rajesh Gopinathan2017–2023
CEO and Managing Director
Under Gopinathan, TCS shares nearly tripled, revenue almost doubled, and profit rose about 60% over his six-year tenure -- one of the strongest CEO track records in Indian corporate history.
Source - K. Krithivasan2023–present
CEO and Managing Director
Under Krithivasan, TCS crossed $30 billion in annual revenue in FY2026 and grew its annualized AI revenue run rate to $2.6 billion by Q1 FY2027, even as dollar revenue was roughly flat amid weak discretionary IT spending.
Source
Timeline: Amgen and TCS side by side
1968TCS
TCS is founded
Tata Consultancy Services begins inside the Tata Group.
1969TCS
F.C. Kohli Joins as First CEO
F.C. Kohli is brought in on deputation to lead TCS, then a 10-consultant operation, and begins building an industrial, assembly-line approach to software delivery.
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2001TCS
CMC Limited Stake Acquired
TCS acquires a majority stake in CMC Limited from the Government of India, adding systems-integration and public-sector technology capability.
2001TCS
TCS Crosses $1 Billion in Revenue
TCS becomes the first Indian IT services company to cross $1 billion in annual revenue, cementing its position as an industry leader.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2004TCS
TCS lists publicly
TCS completes its IPO and becomes one of India's most important listed technology companies.
2009TCS
TCS crosses major global scale thresholds
TCS expands globally across industries and delivery centers under new then-CEO N. Chandrasekaran.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2013TCS
N. Chandrasekaran Becomes CEO
Chandrasekaran becomes CEO, leading TCS through a period of rapid international expansion before his 2017 elevation to Tata Sons chairman.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2020TCS
F.C. Kohli Passes Away
F.C. Kohli, TCS co-founder and first CEO, dies at age 96, having lived to see the company he helped build become one of the worlds largest IT services firms.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2023TCS
K. Krithivasan becomes CEO
K. Krithivasan becomes CEO and managing director of TCS, succeeding Rajesh Gopinathan.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026TCS
FY2026 revenue is reported
TCS reports FY2026 revenue of $30.017B and net margin of 19.8%.
2026TCS
Q1 FY2027 AI run-rate grows
TCS reports Q1 FY2027 revenue of $7.624B and annualized AI revenue of $2.6B.
2026TCS
Tata Sons chairman succession opens
On August 12, 2026, N. Chandrasekaran said he would not seek another term as Tata Sons chairman after February 2027; TCS shares fell about 4% on the news.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
TCS
- W12 Studios2018Undisclosed
- Citigroup Global Services2008$505M
- CMC Limited2001Undisclosed
Questions about Amgen vs TCS
Who is the CEO of Amgen Inc. and Tata Consultancy Services Limited?
Amgen Inc. is led by Robert A. Bradway and Tata Consultancy Services Limited is led by K Krithivasan. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs Tata Consultancy Services Limited?
Tata Consultancy Services Limited was founded in 1968 — 12 years before Amgen Inc., which was founded in 1980. Tata Consultancy Services Limited's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Amgen Inc..
How many employees does Amgen Inc. have compared to Tata Consultancy Services Limited?
Amgen Inc. employs approximately 31,500 people, while Tata Consultancy Services Limited employs approximately 593,798. Tata Consultancy Services Limited has the larger workforce at 593,798 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and Tata Consultancy Services Limited headquartered?
Amgen Inc. is headquartered in United States and Tata Consultancy Services Limited is headquartered in India. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Amgen Inc. and Tata Consultancy Services Limited?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. Tata Consultancy Services Limited was founded by J.R.D. Tata, F.C. Kohli.
Which company has a longer operating history — Amgen Inc. or Tata Consultancy Services Limited?
Tata Consultancy Services Limited has been operating for approximately 58 years, making it the more established of the two companies. Amgen Inc. has been in operation for around 46 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs TCS overview